Zilo+Ibr Combination Shows Promise in John Theurer Cancer Center at Hackensack University Medical Center Study

Phase 1/2 study offers encouraging results for MZL, CLL and MZL

Researchers with John Theurer Cancer Center at Hackensack University Medical Center contributed to an ASH Annual Meeting presentation in December highlighting a Phase 1/2 study of Zilovertamab and ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Several key findings:

• In this study, Zilo+Ibr was well-tolerated with a safety profile similar to Ibr alone.
• While pre-clinical studies showed that Zilo has additive or synergistic activity with targeted agents, such as the Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib (Ibr), this is the first study showing clinical synergy.
• This exploratory study with encouraging results is ongoing, with the addition of MZL pts, and has driven a Phase 3 registrational study evaluating Zilo+Ibr in MCL (ZILO-301).

The humanized monoclonal antibody Zilovertamab (Zilo) inhibits the cancer stem cell antigen, ROR1’s the tumor-promoting activity. ROR1 is highly expressed by hematologic malignancies including MCL and CLL, and by many solid tumors, but not by normal tissue-specific stem cells.

Learn more about innovations in cancer treatments at Hackensack University Medical Center.